Diamond Hill Capital Management Inc. Increases Stock Position in Solventum Corporation $SOLV

Diamond Hill Capital Management Inc. grew its stake in shares of Solventum Corporation (NYSE:SOLV) by 152.2% during the fourth quarter, HoldingsChannel.com reports. The fund owned 2,109,027 shares of the company’s stock after buying an additional 1,272,921 shares during the quarter. Diamond Hill Capital Management Inc.’s holdings in Solventum were worth $167,119,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Solventum by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock valued at $1,249,847,000 after acquiring an additional 867,837 shares during the last quarter. Independent Franchise Partners LLP boosted its holdings in shares of Solventum by 27.2% during the 3rd quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock valued at $941,645,000 after acquiring an additional 2,758,174 shares during the last quarter. State Street Corp boosted its holdings in shares of Solventum by 1.8% during the 3rd quarter. State Street Corp now owns 6,220,271 shares of the company’s stock valued at $454,080,000 after acquiring an additional 112,261 shares during the last quarter. Davis Selected Advisers boosted its holdings in shares of Solventum by 12.7% during the 4th quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock valued at $492,880,000 after acquiring an additional 702,461 shares during the last quarter. Finally, Boston Partners boosted its holdings in shares of Solventum by 26.1% during the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after acquiring an additional 959,543 shares during the last quarter.

Solventum Stock Performance

SOLV opened at $76.81 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. The company has a market cap of $13.30 billion, a price-to-earnings ratio of 9.41, a PEG ratio of 1.18 and a beta of 0.59. The company’s 50 day moving average is $68.50 and its 200 day moving average is $74.76. Solventum Corporation has a 12-month low of $62.38 and a 12-month high of $88.20.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter last year, the firm posted $1.34 earnings per share. The firm’s revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, equities research analysts predict that Solventum Corporation will post 6.57 EPS for the current year.

Insiders Place Their Bets

In other news, Director Amy Mcbride Wendell purchased 1,475 shares of the stock in a transaction on Tuesday, March 10th. The shares were acquired at an average price of $68.03 per share, with a total value of $100,344.25. Following the completion of the acquisition, the director directly owned 5,039 shares of the company’s stock, valued at $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.24% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

SOLV has been the topic of a number of research reports. KeyCorp raised their price objective on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Wedbush initiated coverage on shares of Solventum in a report on Friday, May 15th. They issued an “outperform” rating and a $94.00 price objective on the stock. Wells Fargo & Company dropped their price objective on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 6th. UBS Group downgraded shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a report on Thursday, May 14th. Finally, Piper Sandler dropped their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Eight analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $84.25.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.